Product Name: Bosutinib
Bosutinib Chemical Structure
5 stars, based on 89736 reviews
Price of Bosutinib
We offer a substantial discount on larger orders,
please inquire via firstname.lastname@example.org
or Fax: 1-201-884-1288 (USA Fax#)
Bosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March, 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.
Chemical Formula: C26H29Cl2N5O3
Storage Conditions: 2ºC to 8 ºC, or -20ºC for 3 years.